SLE Mouse Model
Mouse models have contributed to significant progress in uncovering mechanisms by which lupus develops and sustains disease conditions and in evaluations of therapeutic efficacy. Pristane-induced lupus is a well-established model of murine lupus. Disease development following injection of pristane in a variety of mouse strains leads to an inflammatory process resulting in lupus-specific autoantibodies, immune complex deposition and glomerulonephritis.
Treatment efficacy in the Pristane-Induced Mouse Model (PIMM) is evaluated primarily by autoantibody, indirect fluorescent antibody (IFA) assay, urine protein levels and renal pathology. Additional analysis for cytokines may be indicated from the primary readouts.
|SLE Mouse Model|
|A well-established model of murine lupus|
|Study Duration||5 months|
|Read-outs||Observations and body weights twice a week Anti-ds DNA lgG; ANA-IFA|
|Optional||Kidney tissue histology (the severity of the renal lesion). Glomerulonephritis, renal tubular lesions and interstitial inflammation observed.|
Comparison of autoantibody (anti-ds DNA lgG) with pristane application and PBS as control, and prednisone treatment
Antinuclear antibodies in the sera of pristane-treated, control (PBS) and prednisone treatment mice at 5 months after pristane injection were determined by immunofluorescence staining on HEp-2 cells.